Literature DB >> 23592885

RNAi therapeutics and applications of microRNAs in cancer treatment.

Keita Uchino1, Takahiro Ochiya, Fumitaka Takeshita.   

Abstract

RNA interference-based therapies are proving to be powerful tools for combating various diseases, including cancer. Scientists are researching the development of safe and efficient systems for the delivery of small RNA molecules, which are extremely fragile in serum, to target organs and cells in the human body. A dozen pre-clinical and clinical trials have been under way over the past few years involving biodegradable nanoparticles, lipids, chemical modification and conjugation. On the other hand, microRNAs, which control the balance of cellular biological processes, have been studied as attractive therapeutic targets in cancer treatment. In this review, we provide an overview of RNA interference-based therapeutics in clinical trials and discuss the latest technology for the systemic delivery of nucleic acid drugs. Furthermore, we focus on dysregulated microRNAs in human cancer, which have progressed in pre-clinical trials as therapeutic targets, and describe a wide range of strategies to control the expression levels of endogenous microRNAs. Further development of RNA interference technologies and progression of clinical trials will contribute to the achievement of practical applications of nucleic acid drugs.

Entities:  

Keywords:  Cancer; DDS; RNA interference; microRNA

Mesh:

Substances:

Year:  2013        PMID: 23592885     DOI: 10.1093/jjco/hyt052

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  20 in total

1.  Impact of size, secondary structure, and counterions on the binding of small ribonucleic acids to layered double hydroxide nanoparticles.

Authors:  Blanca V Rodriguez; Jorge Pescador; Nicole Pollok; Gary W Beall; Corina Maeder; L Kevin Lewis
Journal:  Biointerphases       Date:  2015-12-30       Impact factor: 2.456

Review 2.  Role of microRNAs in the trabecular meshwork.

Authors:  Pedro Gonzalez; Guorng Li; Jianming Qiu; Jing Wu; Coralia Luna
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-02       Impact factor: 2.671

3.  Studying Protein Function and the Role of Altered Protein Expression by Antibody Interference and Three-dimensional Reconstructions.

Authors:  Kristin Derlig; Andreas Gießl; Johann Helmut Brandstätter; Ralf Enz; Regina Dahlhaus
Journal:  J Vis Exp       Date:  2016-04-21       Impact factor: 1.355

Review 4.  MicroRNAs and their relevance to ABC transporters.

Authors:  Sierk Haenisch; Anneke Nina Werk; Ingolf Cascorbi
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

5.  Factors affecting the association of single- and double-stranded RNAs with montmorillonite nanoclays.

Authors:  Archana Gujjari; Blanca V Rodriguez; Jorge Pescador; Corina Maeder; Gary W Beall; L Kevin Lewis
Journal:  Int J Biol Macromol       Date:  2017-12-22       Impact factor: 6.953

6.  Silencing of DUSP6 gene by RNAi-mediation inhibits proliferation and growth in MDA-MB-231 breast cancer cells: an in vitro study.

Authors:  Hongming Song; Chenyang Wu; Chuankui Wei; Dengfeng Li; Kaiyao Hua; Jialu Song; Hui Xu; Lei Chen; Lin Fang
Journal:  Int J Clin Exp Med       Date:  2015-07-15

7.  MicroRNA-155 expression as a prognostic factor in patients with gallbladder carcinoma after surgical resection.

Authors:  Xue-Lin Zhang; Jun-Hong Chen; Cheng-Kun Qin
Journal:  Int J Clin Exp Med       Date:  2015-11-15

8.  Overexpression of microRNA-155 predicts poor prognosis in glioma patients.

Authors:  Jun Sun; Huachao Shi; Niansheng Lai; Keman Liao; Shuai Zhang; Xiaojie Lu
Journal:  Med Oncol       Date:  2014-03-13       Impact factor: 3.064

9.  Upregulation of miR-183 expression and its clinical significance in human brain glioma.

Authors:  Zhennan Ye; Zihuan Zhang; Lingyun Wu; Cegang Liu; Qiang Chen; Jingpeng Liu; Xiaoliang Wang; Zong Zhuang; Wei Li; Shanshui Xu; Chunhua Hang
Journal:  Neurol Sci       Date:  2016-05-23       Impact factor: 3.307

10.  MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer.

Authors:  N Akanuma; I Hoshino; Y Akutsu; K Murakami; Y Isozaki; T Maruyama; G Yusup; W Qin; T Toyozumi; M Takahashi; H Suito; X Hu; N Sekino; H Matsubara
Journal:  Br J Cancer       Date:  2013-11-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.